Allogene Therapeutics amends Code of Business Conduct and Ethics

Allogene Therapeutics, Inc.

Updates insider trading policy, antitrust restrictions, and conflicts-of-interest procedures.
Expands fair dealing obligations, gift/entertainment restrictions, and data privacy/cybersecurity requirements.
Adds express requirement to comply with all other Company policies supporting the Code.
Applies to all directors, officers, employees, and certain consultants/contractors.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Allogene Therapeutics, Inc.: Amendments to the Company's Code of Business Conduct and Ethics to update and clarify standards, including insider trading policy, antitrust compliance, conflicts of interest, outside business opportunities, record integrity, fair dealing, gifts, asset protection, spokesperson authority, data privac (effective 2024-10-03).

Change: code of ethics
Effective: 2024-10-03

Exact text from the filing

On October 3, 2024, the Audit Committee of the Board of Directors of Allogene Therapeutics, Inc. (the “Company”) adopted and approved certain amendments to the Company’s Code of Business Conduct and Ethics (the “Code”) that applies to all directors, officers, employees and certain consultants and contractors of the Company (“Covered Persons”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-24-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.